#None #DFMO #Aminex Therapeutics #AMXT 1501

Aminex Therapeutics Launches Pioneering Clinical Trial for Cancer Treatment

Aminex Therapeutics, Inc. has proudly announced the start of a Phase 1b/2 clinical trial for its innovative investigational treatment, AMXT 1501, in combination with difluoromethylornithine (DFMO). This multi-center trial is poised to make a significant impact on patients suffering from advanced metastatic melanoma and hormone receptor-positive breast cancer that has proven resistant to prior treatments.

A Crucial Step in Cancer Research

On February 4, 2026, the biotechnology company revealed its latest milestone, underscoring its commitment to developing effective therapies for patients battling rare and challenging cancers. Dr. Mark Burns, the Chief Scientific Officer and President of Aminex, emphasized the importance of this study as a beacon of hope for those facing limited treatment options. The trial aims to assess the safety, tolerability, and preliminary efficacy of oral AMXT 1501 alongside oral DFMO and standard care protocols.

The research will target multiple tumor types and aims to establish a comprehensive understanding of how AMXT 1501 coupled with DFMO can potentially obstruct polyamine metabolism, a crucial process that facilitates tumor growth and compromises immune response.

The Mechanism Behind AMXT 1501

AMXT 1501 represents a novel approach in oncology as it serves as a polyamine transport inhibitor. Polyamines are small organic molecules that tumors rely on for growth and survival. By effectively blocking their uptake, AMXT 1501 has the potential to stifle cancer progression.

DFMO, an established inhibitor of polyamine biosynthesis, offers an additional layer of attack against the cancer cells, working synergistically with AMXT 1501 to inhibit tumor growth comprehensively. The dual approach not only aims to reduce tumor size but also to enhance the body’s immune response to cancer.

Collaboration with Pediatric Researchers

In conjunction with the adult trial, Aminex has partnered with The Beat Childhood Cancer Consortium at Penn State College of Medicine to conduct a randomized Phase 1/2 clinical trial targeting pediatric patients diagnosed with various hard-to-treat cancers, including neuroblastoma and glioma. This reflects Aminex’s overarching goal to extend its innovative cancer therapies to the youngest victims of this devastating disease.

Regulatory Support and Future Outlook

The company also announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the use of AMXT 1501 in combination with DFMO specifically for treating neuroblastoma. This designation not only provides certain benefits in terms of regulatory support and exclusivity but also highlights the FDA's recognition of the urgent need for effective treatments in rare pediatric cancers.

This groundbreaking trial, designated under the clinical trial number NCT07287917, is set to include both safety and dose expansion cohorts, which will allow researchers to gather critical data on these treatments' effects over time. Given the dire need for effective therapies for patients with advanced malignancies, the insights gained from this study could potentially set new standards in cancer care.

In summary, with its innovative approach and commitment to addressing urgent medical needs, Aminex Therapeutics is positioning itself at the forefront of cancer research. The insights and results from the Phase 1b/2 clinical trial could shape the future landscape of cancer treatments, providing new hope for patients and their families.